Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer

by NASDAQ Market News August 3, 2020

NASDAQ Market News
Click here to email author

Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis

Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million

Ads